



BIOMARKERS 2025



30 September - 01 October 2025 | London, UK

Revolutionize your translational research by harnessing cutting-edge biomarker technologies, pioneering strategies, and exclusive interactions with over 1,000 attendees and 120+ key opinion leaders, at the 20th Annual Biomarkers & Precision Medicine Congress.

Key Speakers Include



MOHAMED HASSANEIN,
Director, Translational
Medicine,
Pfizer



ANDREW PIERCE,
Vice President -
Translational Biology,
**Crescendo Biologics
Limited**



RADHA KRISHNAN,
Executive Director,
Clinical Pathology
Lead,
MSD UK



GERARD SANDERINK,
Global Head
Biomarkers and
Clinical Bioanalyses,
Sanofi R&D



DMITRI MIKHAILOV,
Director,
Novartis



KIRI GRANGER,
Chief Scientific
Officer, **Monument
Therapeutics**



LUCIE BRUIJN,
Therapeutic Area
Biomarker Lead,
Novartis



CHRIS CHAMBERLAIN,
Executive Director
Precision Medicine
Discovery &
Development,
AstraZeneca

Complimentary Guest
Passes Are Available

[Book Now](#)



WELCOME TO

Biomarkers 2025

Welcome to the **20th Annual Biomarkers & Precision Medicine Congress**, a pivotal gathering that brings together C-level decision makers with the latest technological strides propelling translational research, clinical trials & development, therapeutic innovation and precision medicine. Celebrating two decades of progress and a 3-day conference programme, this event serves as a dynamic platform where leading minds unite to explore cutting-edge biomarker technologies, pioneering strategies and clinical development success stories. Beyond the latest technology innovations, the congress uniquely offers direct engagement with key opinion leaders, providing unparalleled opportunities for high-level networking, market insights, and facilitating future fruitful collaborations that turn challenges into successes. Do not miss out on participating in this congress to inspire and innovate biomarker research and development in 2025 and beyond.

Benefits to Attending

- ✓ **Gain invaluable insights into the latest advancements** in the integration of biomarkers in early drug development through unique case studies across multiple therapeutic areas. Key opinion leaders will be presenting on NASH, cardiovascular disease detection, rare & autoimmune diseases and oncology, immune-oncology & neuroscience.
- ✓ **Discover collaborative solutions for digital transformation**, digital biomarkers and data-driven approaches. Presentations will cover digital biomarkers for disease detection and monitoring; integration of digital health technologies & devices, AI/ML approaches and RWE & biomarker data analysis.
- ✓ **Discuss the latest innovations in navigating regulatory barriers in clinical trials & CdX and complex biomarkers.** From in vitro diagnostics regulations and quality environment for quality testing through to how regulators can support the development & adoption
- ✓ **Engage in thought-provoking panel discussions** C-level debates, collaborative roundtables & workshops on. Discussion sessions include: 'Biomarker Analysis Techniques'; 'Patient-Centric Biomarkers in Clinical Trials' and 'Reflection When Biomarker Development Fails And Lessons Learnt in Pre-Clinical Development'
- ✓ **Tap into enabling precision medicine** in diagnostics & development. Key opinion leaders will be covering developing nextgen diagnostics methods as well as case studies from oncology, autoimmune diseases and neuroscience



Welcome

Attendees

Sponsors

Session
Topic Areas

Confirmed
Speakers

Innovation &
Collaboration
Track

Forthcoming
Events

Book Now

Network and Knowledge-share

1,000+ VPs, Directors & Senior Managers will be attending on-site and online, coming from leading healthcare, biotech, pharma and research institutions in the following fields and more:


- Next Generation Diagnostics
- Computational Biology
- Clinical & Genomic Biomarkers
- Clinical Cytometry
- Personalised Medicine
- Preclinical Safety
- Regulatory Guidance
- Translational Medicine
- Biomarker Validation
- Flow Cytometry
- Clinical Biomarkers
- Precision Biomarkers

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1-2-1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated refreshment (networking) breaks covering:

- Biomarker Analysis
- Biomarker Validation
- Mass Spectrometry
- Translational Biomarkers
- Clinical Biomarkers
- Assay Development
- Biomarker Quantification
- Multiplex Analysis
- Biomarker Clinical Trials
- Multiplex Platforms
- Companion Diagnostics
- Genomic Biomarkers

Previous Attendee Profile

(Stats from Biomarkers 2023)



Attended by these companies & many more:



Welcome

Attendees

Sponsors

Session Topic Areas

Confirmed Speakers

Innovation & Collaboration Track

Forthcoming Events

Book Now

LinkedIn

@OGConferences

WHO IS SPONSORING?

Drive Innovation & Accelerate Research

Diamond Sponsor



Platinum Sponsor



Gold Sponsors



Silver Sponsors



Bronze Sponsors



Network & Programme Sponsors



Welcome

Attendees

Sponsors

Session Topic Areas

Confirmed Speakers

Innovation & Collaboration Track

Forthcoming Events

Book Now



@OGConferences

Explore Curated & Insightful Content

Biomarkers 2025 features a 3-day programme of in-person cutting-edge presentations and knowledge-sharing. The event will include over 120 industry insights, sponsored presentations & interactive discussion sessions.

Day One | 30 September 2025

Track 1: Biomarkers for NASH, Cardiovascular Diseases Detection

- Novel and emerging biomarkers for the detection of cardiovascular disease
- Developing high-sensitivity cardiac troponin assays
- Non-invasive diagnostic tools in the development of biomarker-based tests for cardiovascular diseases
- Applications of proteomic biomarkers for heart failure, atherosclerosis

Track 2: Biomarkers for Rare & Autoimmune Disease

- Cell & gene biomarkers as innovative approaches to treat rare diseases
- Identifying and diagnosing rare diseases with genetic biomarkers
- Biomarkers for gene therapies
- Biomarkers for patient stratification
- Biomarkers for companion diagnostics
- Case studies in: rheumatic arthritis; IBD; psoriasis
- Auto-antibodies as a diagnostics & research tool

Track 3: Digital Transformation & Digital Biomarkers & Data Science & AI/ML

- Part 1 – Digital Biomarkers
- Digital biomarkers for disease detection and monitoring
 - Measuring novel disease domains with digital biomarkers
 - Accelerating the development of digital biomarkers & adoption
 - Clinical utility & validation of digital biomarkers
 - Integration of digital health technologies & devices
- Part 2 – Data Science
- RWE & biomarker data analysis
 - AI and sampling techniques

Track 4: Navigating Regulatory Barriers in Clinical Trials & CdX and Complex Biomarkers

- In vitro diagnostic regulations
- Integrating complex biomarkers into the clinic and the surrounding regulations
- Clinically relevant biomarkers
- How can regulators support the development and adoption of digital biomarkers?
- Quality environment for biomarker testing & clinical impact & regulatory requirements
- GCLP & how this applies to biomarker analysis in clinical studies

Day Two | 31 September 2025

Track 1: Biomarkers Identification, Validation in Oncology, Immuno-Oncology & Immunology

- Updates in predictive biomarkers for drug development
- Check point inhibitors and dual therapies in immuno-oncology
- Biomarker discovery in oncology and autoimmunity
- Biomarker analysis and validation strategies

Track 2: Enabling Precision Medicine for Diagnostics & Development

- Liquid biopsy biomarkers for disease monitoring, multi-cancer screening & early detection
- Diagnostic-driven therapies: towards the clinic with optimised market access & patient adoption
- Liquid biopsy and its role in precision medicine
- Blood biomarkers for early detection of cancer
- Point-of-care & companion diagnostics development
- Using complex biomarkers in precision oncology

Track 3: Biomarkers for Clinical Development

- Biomarker trial design and data analysis
- Implementing clinical biomarkers in immunology, oncology, cardiology, neuroscience and inflammatory diseases
- Biomarker development gene therapy- patient responses and histology
- Transforming clinical development through biomarker driven clinical trial design
- Use of cellular, transcriptomic and proteomic biomarkers in clinical trials

Track 4: Spatial Tissue Imaging & Imaging and AI for Biomarker Research

- Examining the latest developments in imaging technologies
- Overcoming challenges in image analysis
- Integrating ai into image analysis
- Integrating digital pathology into clinical trials
- Digital multi-omics biomarker profiling
- Tissue-based diagnostics & computational pathology
- Imaging technologies, CNS imaging techniques and digital pathology

Day Three | 01 October 2025

Track 1: Biomarkers Identification & Validation: Neuroscience & Co-Morbidity

- Novel and case studies in biomarker discovery and validation in neuroscience: schizophrenia; CNS
- Novel stem cell & fluid biomarkers for neurodegenerative disorders
- Biomarker analysis, context of use and validation strategies

Track 2: New & Emerging Biomarker Technologies for Biomarker Analysis

- Assay development & validation including multiplexing and flow cytometry
- Multiplexing technologies, flow cytometry and mass spectrometry
- Multi-gene biomarker id through analyses of several orthogonal data sets
- Integrating multi-omics data

Track 3: Biomarkers for Clinical Trials

- Translational biomarkers from preclinical to clinical phase studies
- The role of safety and efficacy biomarkers in translation
- Patient profiling and biosignatures in clinical development
- Patient centric biomarkers in clinical trials
- Transitioning complex biomarkers into the clinic

Track 4: Genomic & Multi-Omic Approaches in Biomarkers Discovery and Development

- Precision oncology and molecular profiling
- Biofluid-based molecular biomarkers: ctDNA and CTCs
- Validating and verifying genomic markers in preclinical drug development
- Predictive and prognostic biomarkers for oncology and rare diseases

Welcome

Attendees

Sponsors

▶ Session Topic Areas

Confirmed Speakers

Innovation & Collaboration Track

Forthcoming Events

Book Now

CONFIRMED SPEAKERS

Gain Expertise from Thought Leaders

TIM AITMAN

Director of the Centre for Genomic and Experimental Medicine, University of Edinburgh, Institute of Genetics and Cancer

CHRIS CHAMBERLAIN

Executive Director Precision Medicine Discovery and Development, AstraZeneca

HENOCH HONG

Associate Director, Merck Healthcare KGaA

GABRIELA KRAMER-MAREK

Associate Professor of Molecular Imaging Institute of Cancer Research

DAVID KRIGE

Head Of Translational Sciences, Accession Therapeutics

ANDREW PIERCE

Vice President, Translational Biology, Crescendo Biologics

THOMAS JENSEN

Chief Executive Officer, Allarity Therapeutics

DMITRI MIKHAILOV

Director, Novartis

KIRA HOLMSTROM

Head Of Biomarker Research, Herantis Pharma

ALEXANDRA SEVKO

Director, Translational Research, Prokarium

KIRI GRANGER

Chief Scientific Officer, Monument Therapeutics

GADY COJOCARA

Director of Biomarker Research/ Computational Discovery, Compugen

VALERIE TALY

Group Leader and CNRS Research Director, INSERM

DONNA FINCH

Head of Translational and Clinical Science, Alchemab Therapeutics

AIDA SANTAOLALLA

Senior Epidemiologist and Senior Data Scientist, King's College London

CHRISTOPHER PETERS

Clinical Senior Lecturer and Consultant Upper GI and General Surgeon, Imperial College London

STEVEN PICCOLI

Head Clinical Biomarkers, SPARC

PATRICK FIVEY

Director of Precision Medicine Policy, AstraZeneca

DEBAYAN MUKHERJEE

Principal Scientist, Spatial Multiplex Imaging, In Vitro/ In Vivo Translation Research - Pharma R&D, GSK

THOMAS HACH

Senior Clinical Development Medical Director, Novartis

ANDERS STAHLBERG

Professor Clinical Genomics, Gothenburg University

EMMA LEIRE

Head of Translational Science Immune Monitoring, Achilles Therapeutics

MARIA UDRISTE SOCEA

Senior Scientist, AstraZeneca



Welcome

Attendees

Sponsors

Session
Topic Areas

Confirmed
Speakers

Innovation &
Collaboration
Track

Forthcoming
Events

Book Now

INSPIRING TOMORROW'S BREAKTHROUGHS

Unleashing Innovation & Collaboration in Biomarkers Research & Development

Join engaging presentations featured in our **innovation and collaboration track running across day 2 and 3**, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies with fewer than 30 employees.

Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:

- ✓ Seeking collaboration partners with pharma and solution providers.
- ✓ Discovering new investment opportunities with pharma.
- ✓ Learning about the latest industry trends & challenges.
- ✓ Keeping updated with new innovations and technology solutions.
- ✓ Showcasing their company profile to a targeted and engaged audience.

Format:

The Innovation & Collaboration track will be comprising of 10-minute presentations and focused panel discussion sessions, encouraging networking, facilitating collaborations & showcasing emerging innovations in biomarkers discovery & development.



Welcome

Attendees

Sponsors

Session
Topic Areas

Confirmed
Speakers

▶ Innovation &
Collaboration
Track

Forthcoming
Events

Book Now

Poster Presentation Awards at Biomarkers 2025:

The Biomarkers Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 20th December 2024 in the below category:

- Emerging Technologies
- Biomarkers in Therapeutics
- Biomarkers in Diagnostics
- Biomarkers in Clinical Trials & Precision Medicine
- Omics-Based Biomarker Discovery

LinkedIn

X @OGConferences



FORTHCOMING EVENTS

BIOMARKERS SERIES ACROSS 2024

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations.



Biomarkers 2024

29 February - 01 March 2024
London, UK

Biomarkers Europe 2024

30 September - 01 October 2024
Basel, Switzerland

Biomarkers US 2024

October 2024
San Diego, USA



Biologics Series

Proteins & Antibodies | Peptides | Oligonucleotides
Sustainability in Biologics | ADC Discovery & Development
Vaccines | Oligonucleotides Chemistry & Therapeutics

Cell & Gene Series

Gene Therapy Development
Cell Culture Advanced Therapy Development
Cell & Gene Therapy Manufacturing

Discovery Series

Organ Modelling | 3D Cell Culture
Drug Discovery Summit & Discovery Chemistry
Neuroscience Drug Development
SmartLabs Automation & Robotics

Formulation & Delivery Series

Formulation & Drug Delivery
Inhalation & Respiratory Drug Delivery
RNA Therapeutics & Delivery

Immuno Series

Advances in Immuno-Oncology
Innate Killer Cells | Oncolytic Virotherapies | Targets &
Cell Types in Immuno-Oncology

Omics Series

Next Generation Sequencing
Single Cell & Spatial Analysis | Synthetic Biology
Next Generation Sequencing & Clinical Diagnostics
Digital PCR & Liquid Biopsies |
Synthetic Biology in Discovery & Therapeutics
Spatial Biology

Visit www.oxfordglobal.com/calendar/
to explore our diverse portfolio of events
across 2024.

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session
Topic Areas

Confirmed
Speakers

Innovation &
Collaboration
Track

Forthcoming
Events

Book Now

OXFORD
GLOBAL

PLUS

12-MONTH CONTENT AND COMMUNITY ACCESS

Oxford Global PLUS Pass

Oxford Global PLUS Pass includes
unrestricted access to all events
shown above and much more

Register Now 

To receive bespoke proposal for group packages
contact us at pluspass@oxfordglobal.com

LinkedIn

@OGConferences